Understanding how anthrax toxin causes death and finding new treatments
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-10995266
This study is looking at how anthrax toxin harms the body and aims to find new treatments that can help people recover even after serious damage has been done, especially when standard treatments aren't working anymore.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10995266 on ClinicalTrials.gov |
What this research studies
This research investigates the lethal effects of anthrax toxin on the body and aims to develop new therapies that can help patients even after severe damage has occurred. The study focuses on the mechanisms by which the anthrax lethal toxin causes harm, particularly in cases where traditional treatments are no longer effective. By exploring these mechanisms, the researchers hope to create targeted therapies that can repair cellular damage and improve survival rates for those affected by anthrax. This work is crucial given the rapid progression of anthrax disease and the high mortality rates associated with it.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been diagnosed with anthrax or are at high risk of exposure to anthrax.
Not a fit: Patients who are not affected by anthrax or those who have already received effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce mortality rates in patients suffering from anthrax.
How similar studies have performed: While there has been significant research on anthrax treatment, this approach focusing on targeted therapies beyond the point of no return is relatively novel and untested.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, SHIHUI — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: LIU, SHIHUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anthrax disease